PTEN Mutations Trigger Resistance to Immunotherapy

Feixiong Cheng; Charis Eng

doi:10.1016/j.molmed.2019.03.003

PTEN Mutations Trigger Resistance to Immunotherapy

Trends Mol Med. 2019 Jun;25(6):461-463. doi: 10.1016/j.molmed.2019.03.003. Epub 2019 Mar 27.

Authors

Feixiong Cheng¹, Charis Eng²

Affiliations

¹ Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Electronic address: [email protected].
² Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, OH 44195, USA; Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA; Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA; Department of Genetics and Genome Sciences, Case Western Reserve University School of Medicine, Cleveland, OH 44106, USA. Electronic address: [email protected].

PMID: 30928438
DOI: 10.1016/j.molmed.2019.03.003

Abstract

Immune checkpoint-blocking antibodies are actively used to treat multiple cancer types; however, the underlying resistance mechanism remains unclear. In a recent study, Zhao et al. (Nat. Med. 2019;25:462-469) found that somatic PTEN mutations were associated with resistance to immune checkpoint inhibitors by altering immunosuppressive environments in patients with glioblastomas.

Keywords: PTEN; combination therapy; glioblastomas; immune checkpoint; immunotherapy resistance.

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents, Immunological / pharmacology
Antineoplastic Agents, Immunological / therapeutic use*
Biomarkers, Tumor
Drug Resistance, Neoplasm / genetics*
Glioblastoma / drug therapy*
Glioblastoma / genetics*
Glioblastoma / immunology
Humans
Immunomodulation / drug effects*
Mutation*
PTEN Phosphohydrolase / genetics*
Tumor Microenvironment / drug effects
Tumor Microenvironment / genetics
Tumor Microenvironment / immunology

Substances

Antineoplastic Agents, Immunological
Biomarkers, Tumor
PTEN Phosphohydrolase
PTEN protein, human

Abstract

Publication types

MeSH terms

Substances

Grants and funding